Core Viewpoint - The National Healthcare Security Administration (NHSA) has recently disclosed multiple cases of pharmaceutical bribery, highlighting the need for stricter oversight and accountability in the healthcare sector [1][5]. Group 1: Bribery Cases - The NHSA reported several bribery cases, including the case of Liu Mouhong, the director of the pharmacy department at Shuangshan Hospital in Anshan, and others involving significant sums of money [1][4]. - In the case involving a Shanghai trading company, a total of RMB 662.55 million was paid as kickbacks to Wu Mouli, a director at Hebei Medical University Second Hospital, with cash delivered in brown paper bags [2][3]. - Huang Mouyun, responsible for sales of a traditional Chinese medicine product, paid kickbacks totaling RMB 163.63 million to 15 doctors at a hospital to boost sales [4]. Group 2: Regulatory Actions - The NHSA plans to implement a credit rating system for companies involved in bribery and illegal sales practices, which will include restrictions on their ability to participate in public procurement and distribution [5][6]. - The NHSA aims to guide local healthcare authorities in conducting credit ratings and ensuring that companies take corrective actions to address their misconduct [6].